MX2019000003A - Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda. - Google Patents

Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.

Info

Publication number
MX2019000003A
MX2019000003A MX2019000003A MX2019000003A MX2019000003A MX 2019000003 A MX2019000003 A MX 2019000003A MX 2019000003 A MX2019000003 A MX 2019000003A MX 2019000003 A MX2019000003 A MX 2019000003A MX 2019000003 A MX2019000003 A MX 2019000003A
Authority
MX
Mexico
Prior art keywords
subject
congestion
intervention
therapy
heart failure
Prior art date
Application number
MX2019000003A
Other languages
English (en)
Inventor
Bergmann Andreas
Voors Adriaan
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of MX2019000003A publication Critical patent/MX2019000003A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La materia objeto de la presente invención es un método para a) diagnosticar congestión o evaluar o monitorear la extensión de congestión en un individuo o, b) predecir o determinar o monitorear la necesidad de terapia o intervención o predecir o determinar o monitorear el éxito de una terapia o intervención por congestión o guiar una terapia o intervención en un individuo o, c) predecir la descongestión o congestión residual después de terapia o intervención por congestión en un individuo o, d) evaluar la descongestión o congestión residual después de terapia o intervención por congestión en un individuo o, e) evaluar la decisión de dar de alta del hospital a un individuo, en el cual dicho individuo es un individuo que tiene insuficiencia cardiaca aguda que es cualquiera de AHF de reciente inicio o HF descompensada aguda o HF crónica descompensada aguda o en el cual dicho individuo es un individuo que tiene insuficiencia cardiaca crónica con empeoramiento de los signos/síntomas de insuficiencia cardiaca crónica y en el cual se utiliza proadrenomedulina o fragmentos de la misma de por lo menos 5 aminoácidos como un marcador substituto temprano para congestión.
MX2019000003A 2016-07-08 2017-07-07 Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda. MX2019000003A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16178725 2016-07-08
EP16199092 2016-11-16
PCT/EP2017/067091 WO2018007588A1 (en) 2016-07-08 2017-07-07 Adrenomedullin for assessing congestion in a subject with acute heart failure

Publications (1)

Publication Number Publication Date
MX2019000003A true MX2019000003A (es) 2019-08-29

Family

ID=59366410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000003A MX2019000003A (es) 2016-07-08 2017-07-07 Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.

Country Status (12)

Country Link
US (1) US20190376985A1 (es)
EP (2) EP4231018A3 (es)
JP (2) JP7191813B2 (es)
CN (1) CN109716136B (es)
AU (1) AU2017294549C1 (es)
BR (1) BR112019000199A2 (es)
CA (1) CA3030214A1 (es)
ES (1) ES2948446T3 (es)
MX (1) MX2019000003A (es)
RU (1) RU2019103403A (es)
SG (1) SG11201900133WA (es)
WO (1) WO2018007588A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3438668A1 (en) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
DK3682247T3 (da) 2017-09-13 2022-03-21 Brahms Gmbh Proadrenomedullin som markør for unormale blodpladeniveauer
KR20200135947A (ko) * 2018-02-08 2020-12-04 스핑고텍 게엠베하 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
EP3608673A1 (en) * 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
EP4023218A1 (en) 2020-12-02 2022-07-06 S-Form Pharma Combination therapy for patients having acute and/or persistent dyspnea

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
BR0212256A (pt) 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
CA2580881A1 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag Use of microproteins as tryptase inhibitors
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
KR101698362B1 (ko) 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
CN102317790B (zh) * 2008-11-11 2014-12-10 B.R.A.H.M.S有限公司 Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用
DK2427764T3 (en) * 2009-05-05 2017-09-11 Brahms Gmbh VASOACTIVE HORMON-BASED STRATIFICATION OF PATIENTS SUFFERING OF DISEASES RELATED TO ENDOTELIAL FUNCTION / DYSFUNCTION
NZ598351A (en) 2009-08-27 2014-08-29 Covagen Ag Il-17 binding compounds and medical uses thereof
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
KR102249078B1 (ko) * 2011-11-16 2021-05-10 아드레노메드 아게 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
CN105102985B (zh) * 2013-03-20 2018-05-18 斯弗因高泰克有限公司 用于指导血压下降疗法的肾上腺髓质素
JP7270912B2 (ja) * 2017-05-22 2023-05-11 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬

Also Published As

Publication number Publication date
ES2948446T3 (es) 2023-09-12
US20190376985A1 (en) 2019-12-12
EP4231018A2 (en) 2023-08-23
WO2018007588A1 (en) 2018-01-11
RU2019103403A (ru) 2020-08-10
RU2019103403A3 (es) 2020-10-01
SG11201900133WA (en) 2019-02-27
AU2017294549C1 (en) 2023-10-26
CA3030214A1 (en) 2018-01-11
AU2017294549A1 (en) 2019-01-24
CN109716136A (zh) 2019-05-03
JP7191813B2 (ja) 2022-12-19
EP4231018A3 (en) 2023-11-15
EP3482208A1 (en) 2019-05-15
EP3482208B1 (en) 2023-04-12
CN109716136B (zh) 2023-09-22
JP2022122924A (ja) 2022-08-23
BR112019000199A2 (pt) 2019-04-16
AU2017294549B2 (en) 2023-04-20
JP2019530851A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
MX2019000003A (es) Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda.
WO2018089693A3 (en) Methods for determining and monitoring gastrointestinal inflammation
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
EP3470848A3 (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
IN2014DN07813A (es)
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
MX2019012419A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
PH12021550729A1 (en) Method, apparatus and computer program
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
WO2016066862A3 (en) A method for predicting the risk of obesity in a subject
WO2018022604A3 (en) Methods of diagnosing and treating alzheimer's disease with s-equol
MX2019014441A (es) Un metodo in vitro para diagnosticar o monitorear la funcion renal o diagnosticar disfuncion renal.
MX2020012480A (es) Niveles de la proteina de choque termico 70 (hsp70) en las muestras de celulas mononucleares de la sangre periferica (pbmc) como biomarcador para enfermedades.
MX2018006250A (es) Biomarcador de enfermedad poliquistica renal y usos del mismo.
UA129891U (uk) Спосіб прогнозування прогресування хронічної серцевої недостатості у хворих зі збереженою фракцією викиду лівого шлуночка, гіпонатріємією та супутнім ожирінням
O’Malley et al. Schooling CM, Au Yeung SL, Freeman G. Mendelian randomization estimates may be inflated. J Am Coll Cardiol
Lee et al. B44 COPD: COMORBIDITIES: Depression Is A Significant Predictor In Both Disease-Specific And Generic Health Related Quality Of Life In Patients With Severe Chronic Obstructive Pulmonary Disease
WO2019053116A8 (en) Method for guidance of fluid therapy based on proadrenomedullin
RU2014119325A (ru) Способ прогнозирования риска хронизации фибрилляции предсердий у пациентов с сердечно-сосудистыми заболеваниями
UA104421U (uk) Спосіб прогнозування зрощення перелому
UA117186C2 (uk) Спосіб діагностики рецидиву захворювання у хворих на рак ободової кишки
MX2015013851A (es) Uso de auto-anticuerpos contra citoqueratina 19 para el diagnostico de cáncer de pulmon.